Purdue Pharma third party releases: A bitter pill to swallow, Eurofenix, Autumn 2023

Download Eurofenix article here.

David Conaway reports on a recent Chapter 11 plan of reorganization submitted by Purdue Pharma (Oxycontin) to resolve a mass tort claim.

Related Insights

February 10, 2025 | Publication

Client Alert: Navigating FINRA’s 2025 Third-Party Risk Updates: Compliance Strategies for Financial Institutions

January 27, 2025 | Publication

“After Purdue Pharma: The future of third-party releases in the U.S.,” Eurofenix, Winter 2024/25

January 23, 2025 | Publication

Client Alert: After Purdue Pharma: Future of Third-Party Releases in the U.S./ Impact on Cross-Border Insolvencies

View All Insights